Content
82%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
A well-structured, highly actionable domain skill: every phase is backed by concrete executable tool calls and the cause/consequence and evidence-grading frameworks give consistent interpretation guidance. The main improvement levers are trimming a few platitudinous sentences and moving reference-heavy material (gene lists, drug clinical status) into a separate reference file.
Suggestions
Trim universally-known platitudes (e.g., 'A database-verified answer is always more reliable than a guess') and tighten the 'Aging Research Reasoning' prose to raise conciseness toward anchor 5.
Move reference-style tables — the hallmark gene lists in Phase 1 and the per-drug clinical status in Phase 4 — into a references/ file (e.g., references/hallmarks.md, references/senolytics.md) and link them from the body, keeping SKILL.md a leaner overview.
Add explicit validation checkpoints to the workflow (e.g., confirm a tool returned non-empty results before building the report, or re-query with a synonym when a GWAS term misses) to raise workflow_clarity from 4 to 5.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The body is dense with non-obvious domain knowledge Claude cannot reliably recall (KEGG pathway IDs, the FOXO3 targeted-genotyping GWAS-Catalog caveat, per-drug clinical trial status), with only minor trimmable platitudes such as 'A database-verified answer is always more reliable than a guess' — efficient with minor over-explanation, matching anchor 4 rather than the fully lean anchor 5. | 4 / 5 |
Actionability | Fully executable, copy-paste-ready tool calls throughout — 'OpenGenes_get_gene(symbol="FOXO3")', 'KEGG_get_pathway_genes(pathway_id="hsa04218")', 'STRING_get_network(identifiers="\r".join(sasp_genes), species=9606)', 'search_clinical_trials(condition="senescence", query_term="senolytic")' — annotated with comments and covering the common query cases, matching the top anchor. | 5 / 5 |
Workflow Clarity | A clear Phase 0–6 sequence is laid out in the workflow diagram and mirrored by matching sections, with the cause-vs-consequence test and T1–T4 evidence grading serving as interpretation checkpoints and an 8-part report structure; however, no explicit verify-output/retry steps exist, matching anchor 4 ('most checkpoints present; minor validation gaps') rather than 5. | 4 / 5 |
Progressive Disclosure | No bundle files exist and the single file is well-organized with clear section headers and a dedicated limitations section; but at ~185 lines, reference-style material (hallmark gene lists, per-drug clinical status) is inlined where a references/ file would keep the overview leaner — good structure with minor organization gaps, anchor 4 rather than 5. | 4 / 5 |
Total | 17 / 20 Passed |